SAUDI-ECONOMY-PLANNING
29.4.2024 23:03:34 CEST | Business Wire | Press release
Riyadh hosted more than 1,000 global leaders for the two-day World Economic Forum (WEF) Special Meeting in Riyadh, where leading political, economics, energy and technology figures called for clear pathways to stability, prosperity and inclusive growth opportunities in the face of rising cross-border challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429767765/en/
Saudi Minister of Economy and Planning His Excellency Faisal Alibrahim announces Saudi Arabia will join the AI Governance Alliance to co-launch the ‘Inclusive AI Initiative for Growth and Development’ (Photo: AETOSWire)
The more than 1,000 participants in for the WEF Special Meeting on Global Collaboration, Growth and Energy for Development made it the highest-ever number of registrations for a WEF event hosted outside of its Annual Meeting venue in Davos Klosters, Switzerland.
The Special Meeting set the stage for the launch of several initiatives in the fields of healthcare, artificial intelligence, space and sustainability. On the final day of the meeting, chief executive officer of Moderna, Stéphane Bancel, said the American pharmaceutical company is working to have the first product for cancer on the healthcare market, potentially as early as 2025.
On the first day of the meeting, the Saudi Ministry of Health signed a memorandum of understanding with the Bill & Melinda Gates Foundation to ensure equitable access to healthcare services for all, and to deliver more vaccines against polio, measles, and other vital health services to millions of children worldwide. It was one of several agreements signed by the Foundation with the Kingdom to improve global health systems and access.
During the final plenary session, Saudi Arabia’s Minister of Economy and Planning His Excellency Faisal Alibrahim announced that the Kingdom joined the AI Governance Alliance, and will co-launch the ‘Inclusive AI Initiative for Growth and Development’, to develop solutions for AI access and adoption.
The Saudi Space Agency also announced that it will launch the Center for Space Futures in the Kingdom later this year, in collaboration with WEF. The Center will serve as a platform for public-private dialogues and foster the growth of the global space economy.
A Saudi Arabia-led Sustainability Champions Network was also launched on the sidelines of the Special Meeting to accelerate Saudi’s private sector decarbonization efforts.
Saudi Arabia also announced an extension to its collaboration with WEF’s innovation platform UpLink, with two new initiatives that focus on developing solutions to reducing emissions through the circular carbon economy and regenerating the world’s oceans through blue economy innovations.
WEF President Børge Brende hailed the Special Meeting in Riyadh a consequential gathering that drew the attendance of key global leaders including the President of Palestine, Mahmoud Abbas; United States Secretary of State, Anthony Blinken; the United Kingdom’s Foreign Secretary, David Cameron.
Leading philanthropist Bill Gates joined a session on “Bridging the Health Gap”, alongside Dr. Tedros Adhanom Ghebreyesus Director-General, World Health Organization (WHO), and Fahad bin Abdurrahman Al-Jalajel, Minister of Health, Ministry of Health of Saudi Arabia.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429767765/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom